Integrated analysis of genome-wide miRNAs and targeted gene expression in esophageal squamous cell carcinoma (ESCC) and relation to prognosis

Table 3 Survival by miRNA expression for 39 dysregulated miRNAs (from Table 1)^a,b,c,d

No.	miRNA	HR	95% CI	P-value
1	hsa-miR-30e*	*0.76*	*0.61–0.95*	*0.0179*
2	*hsa-miR-124*	*0.79*	*0.62–1.00*	*0.0459*
3	hsa-miR-22	1.22	0.95–1.56	0.1166
4	hsa-miR-140-3p	0.84	0.67–1.05	0.1303
5	hsa-miR-143	0.85	0.68–1.06	0.1487
6	hsa-miR-150	0.85	0.67–1.08	0.1924
7	hsa-miR-106b	1.16	0.92–1.45	0.2022
8	hsa-miR-203	1.15	0.92–1.44	0.2197
9	hsa-miR-596	0.87	0.69–1.09	0.2285
10	hsa-miR-30a*	0.88	0.71–1.09	0.2389
11	hsa-miR-23b	0.88	0.70–1.10	0.2638
12	hsa-miR-183*	1.15	0.89–1.48	0.2763
13	hsa-miR-204	0.88	0.69–1.12	0.2852
14	hsa-miR-486-5p	0.89	0.69–1.13	0.3295
15	hsa-miR-196b	0.89	0.71–1.13	0.3435
16	hsa-miR-145	0.90	0.73–1.12	0.3544
17	hsa-miR-133b	0.90	0.72–1.12	0.3565
18	hsa-miR-133a	0.90	0.72–1.13	0.3815
19	hsa-miR-26b*	0.89	0.68–1.18	0.4180
20	hsa-miR-21*	1.09	0.87–1.37	0.4533
21	hsa-miR-885-5p	1.08	0.85–1.38	0.5286
22	hsa-miR-130b	1.08	0.84–1.39	0.5384
23	hsa-miR-639	1.09	0.83–1.43	0.5404
24	hsa-miR-21*	1.07	0.86–1.34	0.5411
25	hsa-miR-423-5p	1.07	0.84–1.37	0.5707
26	hsa-miR-95	0.94	0.74–1.19	0.5844
27	hsa-miR-708	0.95	0.75–1.20	0.6622
28	hsa-miR-378*	1.05	0.84–1.32	0.6677
29	hsa-let-7c	0.95	0.76–1.20	0.6779
30	hsa-miR-328	0.95	0.74–1.21	0.6869
31	hsa-miR-574–3p	0.95	0.75–1.21	0.6977
32	hsa-miR-139-5p	0.96	0.77–1.20	0.7210
33	hsa-miR-375	1.04	0.81–1.33	0.7731
34	hsa-miR-149	0.97	0.76–1.22	0.7813
35	hsa-miR-125b	0.97	0.77–1.23	0.8095
36	hsa-miR-99a*	1.01	0.81–1.26	0.9020
37	hsa-miR-422a	0.99	0.79–1.23	0.9074
38	hsa-miR-100	1.01	0.80–1.26	0.9548
39	hsa-miR-378	1.00	0.80–1.26	0.9770

^amiRNA expression modeled as tumor/normal fold change using ordinal variable (0,1,2,3)
^bmiRNAs shown in ascending order by P-value
^cCox proportional hazards models adjusted for age, gender, metastasis, stage
^dAssociations P < 0.05 are bolded and italicized

ISSN: 1471-2407